Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.48 EUR | -0.54% | +1.92% | +30.91% |
08:06am | IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court | MT |
05-07 | Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 62.02 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.91% | 66.36B | - | ||
+31.83% | 588B | B | ||
-3.42% | 364B | C+ | ||
+18.02% | 326B | B- | ||
+4.27% | 285B | C+ | ||
+15.32% | 239B | B+ | ||
+10.00% | 210B | B- | ||
-7.03% | 200B | A+ | ||
+8.12% | 167B | C+ | ||
-1.42% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4568 Stock
- D4S Stock
- Ratings Daiichi Sankyo Co., Ltd.